About Amplyx Pharmaceuticals
Amplyx Pharmaceuticals is a company based in San Diego (United States) founded in 2006 was acquired by Pfizer in April 2021. Amplyx Pharmaceuticals has raised $144.31 million across 20 funding rounds from investors including Pfizer, HHS and Arix Bioscience. The company has 15 employees as of December 31, 2015. Amplyx Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Biosergen, Elion Therapeutics and Mycovia Pharmaceuticals, among others.
- Headquarter San Diego, United States
- Employees 15 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Amplyx Pharmaceuticals Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has successfully raised a total of $144.31M across 20 strategic funding rounds. The most recent funding activity was a Series C round of $91.33 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Amplyx Pharmaceuticals
Amplyx Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, HHS and Arix Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Investments in biotech startups are made by Arix Bioscience.
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Amplyx Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Amplyx Pharmaceuticals
Investment portfolio details for Amplyx Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Amplyx Pharmaceuticals
Detailed financials for Amplyx Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Amplyx Pharmaceuticals Comparisons
Peer comparison for Amplyx Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Amplyx Pharmaceuticals
Amplyx Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Biosergen, Elion Therapeutics and Mycovia Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| Locked | Locked | Locked |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| Locked | Locked | Locked |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.
|
Detailed competitors of Amplyx Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Amplyx Pharmaceuticals
Complete news archive for Amplyx Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Amplyx Pharmaceuticals
Amplyx Pharmaceuticals was founded in 2006 and raised its 1st funding round 2 years after it was founded.
Amplyx Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Mike Grey is the current CEO of Amplyx Pharmaceuticals.
Amplyx Pharmaceuticals is a funded company, having raised a total of $144.31M across 20 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Amplyx Pharmaceuticals is 15.
Amplyx Pharmaceuticals is US-based, clinical stage biopharma developing broad-spectrum small molecule fungal enzyme inhibitors. The companys lead compound, APX001 (completed Phase I trials) has shown broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus, as well as high potency against rare, difficult-to-treat molds. APX001 targets the GWT1 enzyme required for glycophosphatidylinositol (GPI) anchor biosynthesis- this cellular process is required for the anchoring of proteins to both the fungal cell wall and cell membrane and is specific to fungi (not humans). By targeting this, the drug leads to errors in the cell wall of the fungi and their death.
Amplyx Pharmaceuticals has 15 investors. Key investors include Pfizer, HHS, Arix Bioscience, Sofinnova, and NEA.